Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Current Assets (2016 - 2020)

Monopar Therapeutics (MNPR) has disclosed Current Assets for 5 consecutive years, with $18.1 million as the latest value for Q3 2020.

  • Quarterly Current Assets rose 254.05% to $18.1 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Sep 2020, up 254.05% year-over-year, with the annual reading at $13.2 million for FY2019, 82.42% up from the prior year.
  • Current Assets hit $18.1 million in Q3 2020 for Monopar Therapeutics, up from $12.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $18.1 million in Q3 2020 to a low of $2.1 million in Q4 2016.
  • Historically, Current Assets has averaged $8.9 million across 5 years, with a median of $7.9 million in 2018.
  • Biggest five-year swings in Current Assets: skyrocketed 335.82% in 2017 and later crashed 35.23% in 2019.
  • Year by year, Current Assets stood at $2.1 million in 2016, then surged by 335.82% to $9.1 million in 2017, then dropped by 20.58% to $7.3 million in 2018, then surged by 82.42% to $13.2 million in 2019, then skyrocketed by 36.72% to $18.1 million in 2020.
  • Business Quant data shows Current Assets for MNPR at $18.1 million in Q3 2020, $12.7 million in Q2 2020, and $12.7 million in Q1 2020.